Show/Hide Menu

MorphoSys's
therapeutic pipeline

You are here

With currently more than 100 distinct drugs in research and development, MorphoSys has one of the broadest pipelines in the biotechnology industry, including unique approaches that aim to help patients with conditions such as cancer, Alzheimer’s disease, infectious diseases, cardiovascular dysfunction and inflammation.

More than 20 therapeutic antibodies are being evaluated by MorphoSys and its partners in clinical trials as novel treatment options for severe and in many cases life-threatening diseases. Several of these in-house and partnered programs have already demonstrated exciting prospects for diseases where currently no proper treatment is available.
MorphoSys continues to expand its portfolio of unique drug candidates and is looking for partners with innovative targets, supportive technologies and promising antibodies for further development.

 

Clinical Pipeline

  • Proprietary Programs
  • Partnered Programs
  • Phase 1
  • Phase 2
  • Phase 3
  • Market
24 Antibodies available:
Program
Partner
Indication
Phase

Partner

Not partnered

Indication

Phase

Acute lymphoblastic leukemia
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Non-Hodgkin lymphoma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Chronic lymphocytic leukemia
Phase 1 Phase 2 (Current Phase) Phase 3 Market

MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.

In June 2010, MorphoSys AG and US-based biopharmaceutical company Xencor signed a worldwide exclusive license and collaboration agreement for the antibody. The agreement provided MorphoSys with an exclusive worldwide license to XmAb5574 for the treatment of cancer and other indications.

Partner

GlaxoSmithKline

Indication

Phase

Inflammatory Diseases
Phase 1 Phase 2 (Current Phase) Phase 3 Market

MOR103 (GSK3196165) is a fully human HuCAL antibody directed against GM-CSF (granulocytemacrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases, i.e. rheumatoid arthritis, where current treatment options are inadequate. Due to its diverse functions in the immune system, GM-CSF can be considered a target for a broad spectrum of anti-inflammatory therapies. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline.

Partner

Not partnered

Indication

Phase

Multiple myeloma
Phase 1 Phase 2 (Current Phase) Phase 3 Market

In preclinical studies, MOR202 mediated antibody-dependent cell-mediated cytotoxicity in MM cells derived from patients in vitro.  Either Velcade® (bortezomib) or Revlimid® (lenalidomide) enhanced the cytotoxic activity of MOR202 in vitro and also the inhibition of MM-mediated bone lysis and tumor load in vivo. The enhancement by bortezomib was mediated through a direct cytotoxic effect on MM cells.

Lenalidomide synergistically enhanced MOR202 activity by several mechanisms identified to be direct cytotoxicity, activation of effector cells and increased CD38 expression levels on MM cells. In an orthotopic xenograft murine model of multiple myeloma, MOR202 reduced tumor load and tumor mediated bone lysis. Co-administration of MOR202 with either bortezomib or lenalidomide completely abolished bone lysis in a synergistic manner. These findings support further investigation of MOR202 combination regimens in clinical trials. MOR202 is currently being tested in a phase 1/2a trial in patients with relapsed/refractory myeloma.

Partner

Emergent BioSolutions

Indication

Phase

Metastatic, castration-resistant prostate cancer (mCRPC)
Phase 1 (Current Phase) Phase 2 Phase 3 Market

MOR209/ES414 is a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer. The immunotherapeutic protein activates the patients’ T-cell immunity specifically against prostate cancer cells expressing Prostate Specific Membrane Antigen (PSMA), an antigen commonly overexpressed in this tumor.

MOR209/ES414 is part of MorphoSys’s collaboration with Emergent BioSolutions to jointly develop the compound.

Partner

Novartis

Indication

Phase

Sporadic inclusion body myositis (52 weeks)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Sporadic inclusion body myositis (long-term study)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Cachexia (COPD)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Cachexia (cancer)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Hip fracture surgery
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Sarcopenia
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat musculoskeletal diseases
  • Target: ActRIIB
  • Aliases: BYM338

Additional information:

Partner

Janssen/J&J

Indication

Phase

Psoriasis (NAVIGATE)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Psoriasis (VOYAGE 1)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Psoriasis (VOYAGE 2)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Psoriasis (Japan)
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Generalized pustular or erythrodermic psoriasis
Phase 1 Phase 2 Phase 3 (Current Phase) Market
Active psoriatic arthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Palmoplantar pustulosis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Rheumatoid arthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat Psoriasis and Rheumatoid Arthritis
  • Target: IL23p19
  • Aliases: CNTO1959

Additional Information:

BHQ880

Partner

Novartis

Indication

Phase

MM (renal insufficiency)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Smoldering MM
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat osteolytic bone disease in multiple myeloma patients
  • Target: Dickkopf-1 (DKK-1)

Additional Information:

BPS804

Partner

Novartis/Mereo

Indication

Phase

Brittle bone disease
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat bone diseases
  • Target: Sclerostin

Additional information:

CNTO3157

Partner

Janssen/J&J

Indication

Phase

Asthma
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Safety / Pharmacokinetics
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat Asthma

Additional Information:

CNTO6785

Partner

Janssen/J&J

Indication

Phase

COPD
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Rheumatoid arthritis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat Inflammatory Diseases

Additional Information:

LFG316

Partner

Novartis

Indication

Phase

Wet AMD
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Geographic atrophy
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Multifocal Choroiditis and Panuveitis
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody developed in Ophthalmology 
  • Target: C5

Additional Information:

LJM716

Partner

Novartis

Indication

Phase

ESCC (combo with BYL719)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
HER2 + cancer (combo with BYL719 & trastuzumab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
HER2 + cancer, combination with trastuzumab
Phase 1 (Current Phase) Phase 2 Phase 3 Market
HER2 + cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Advanced solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat cancer
  • Target: HER3

Additional information:

Tarextumab

Partner

OncoMed

Indication

Phase

Pancreatic cancer (ALPINE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Small cell lung cancer (PINNACLE)
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat pancreatic cancer and small cell lung cancer
  • Target: Notch receptor (Notch 2)
  • Alias: OMP-59R5

Additional Information:

VAY736

Partner

Novartis

Indication

Phase

Pemphigus vulgaris
Phase 1 Phase 2 (Current Phase) Phase 3 Market
Primary Sjörgen's syndrome
Phase 1 Phase 2 (Current Phase) Phase 3 Market
  • A fully human HuCAL antibody to treat inflammatory diseases
  • Target: BAFF-R

Additional information:

Anetumab Ravtansine

Partner

Bayer HealthCare

Indication

Phase

Solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL-based antibody drug conjugate to treat mesotheliomas and ovarian and pancreatic carcinomas
  • Target: Mesothelin
  • Alias: BAY94-9343​

Additional Information:

BI-836845

Partner

Boehringer Ingelheim

Indication

Phase

Solid tumors, Japanese patients
Phase 1 (Current Phase) Phase 2 Phase 3 Market
EGFR mutant NSCLC
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Breast cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
CRPC + enzalutamide
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Various solid cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Advanced solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat cancer
  • Target: IGF-1

Additional Information:

NOV-7

Partner

Novartis

Indication

Phase

Eye disease
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-8

Partner

Novartis

Indication

Phase

Inflammation
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-9

Partner

Novartis

Indication

Phase

Diabetic eye disease
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-10

Partner

Novartis

Indication

Phase

Cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market

NOV-11

Partner

Novartis

Indication

Phase

Blood disorders
Phase 1 (Current Phase) Phase 2 Phase 3 Market

PF-05082566

Partner

Pfizer

Indication

Phase

Advanced solid tumors, combination with mogamulizumab
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors, combination with PD-1 inhibitor MK-3475
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Solid tumors, NHL (+rituximab)
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat cancer
  • Target: 4-1BB (CD137)

Additional Information:

Vantictumab

Partner

OncoMed

Indication

Phase

Solid tumors
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Breast cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Pancreatic cancer
Phase 1 (Current Phase) Phase 2 Phase 3 Market
Non-small-cell lung carcinoma
Phase 1 (Current Phase) Phase 2 Phase 3 Market
  • A fully human HuCAL antibody to treat solid tumors
  • Target: Wnt signaling pathway (Fzd 7)
  • Alias: OMP-18R5

Additional information:

Additionally, MorphoSys currently has various proprietary and partnered programs in the discovery or preclinical phase (July 30, 2015: 51 programs in discovery, 28 programs in preclinic)